奥沙利铂联合替吉奥方案在晚期结直肠癌治疗中的效果及毒副作用对比分析
摘要
目的:探讨奥沙利铂联合替吉奥方案在晚期结直肠癌患者中的临床疗效及对毒副反应发生率的影响。方法:选择2017年7月-2018年5月笔者所在医院治疗的晚期结直肠癌患者72例作为对象,按随机数字表分为对照组(n=36)和观察组(n=36)。对照组给予CapeOX化疗方案治疗,观察组采用奥沙利铂联合替吉奥方案化疗,3个周期后对患者疗效进行评估,比较两组近期疗效、细胞因子及毒副反应发生率。结果:观察组治疗3个周期的近期疗效率为52.78%与对照组的47.22%比较,差异无统计学意义(P>0.05);两组治疗后3周IL-2、IFN-γ、IL-4及IL-6水平比较差异无统计学意义(P>0.05);观察组与对照组治疗后3周期IL-2、TNF-γ水平,均高于治疗前(P<0.05);观察组与对照组治疗后3个周期IL-4水平,低于治疗前(P<0.05);两组治疗期间骨髓抑制、口腔黏膜病变及胃肠道反应发生率无统计学意义(P>0.05);观察组治疗期间手足综合征、肝损伤发生率,低于对照组(P<0.05)。结论:将奥沙利铂联合替吉奥方案用于晚期结直肠癌患者中能获得较高的近期疗效,有助于改善细胞因子水平,毒副反应发生率较低,值得推广应用。
引文
[1]李云霞,高茜,王琳琳.奥沙利铂联合替吉奥或卡培他滨治疗结直肠癌的临床研究[J].中国临床药理学杂志,2016,32(11):978-980.
[2]孙翠玲,徐晓宇,高莹莹,等.奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性[J].中国临床药理学杂志,2017,33(16):1540-1542.
[3]Kap E J,Seibold P,Scherer D,et al.SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients[J].International Journal of Cancer,2016,138(12):2993-3001.
[4]宗明珠,冯婉婷,于伟勇,等.奥沙利铂联合卡培他滨或替吉奥治疗晚期结直肠癌临床疗效的比较[J].肿瘤,2018,38(3):229-234.
[5]左富义,于波,聂玉辉.替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂方案治疗结直肠癌的疗效比较研究[J].中国全科医学,2017,20(29):3612-3616.
[6]Wein A,Siebler J,Wolff K,et al.Weekly High-dose 5-Fluorouracil as24-hour Infusion Combined with Sodium Folinic Acid(AIO regimen)Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer(CRC)[J].Anticancer Research,2017,37(7):3771.
[7]沈旭东,庄志祥,甘蕾,等.每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析[J].肿瘤防治研究,2016,43(5):400-403.
[8]刘君,肖扬,郭建雄,等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究,2016,43(1):72-77.
[9]万一元,惠红霞,王晓炜,等.卡培他滨或替吉奥联合奥沙利铂方案治疗进展期胃癌的疗效及安全性[J].中华肿瘤杂志,2016,38(1):28-34.
[10]展军.奥沙利铂联合替吉奥方案与XELOX方案在晚期结直肠癌治疗中的疗效及毒副作用对比[J/OL].临床医药文献电子杂志,2016,3(59):11865-11866.
[11]Chen J,Luo X,Xie G,et al.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy[J].Medicine,2016,95(19):e3652.
[12]李方,李楠.华蟾素胶囊联合奥沙利铂、替吉奥方案治疗中晚期结直肠癌临床疗效[J].临床军医杂志,2016,44(10):1033-1036.
[13]张瑞亮,李文见,姜统杰.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者疗效对比[J].癌症进展,2017,15(2):196-198.
[14]宁洁,焦洋,李敏,等.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的疗效及安全性研究[J].安徽医药,2017,21(9):1669-1673.
[15]Fernandes G D S,Braghiroli M I,Artioli M,et al.Combined oxaliplatin,irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer patients[J].Annals of Oncology,2016,27(suppl 2):ii45-ii46.
[16]李响.奥沙利铂联合替吉奥与雷替曲塞治疗晚期结肠癌患者的疗效观察[J].中国现代药物应用,2017,11(17):91-92.
[17]李鹏,李成浩.奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效观察[J].中国实用医药,2017,12(7):143-144.
[18]Kataoka M,Kanda M,Ishigure K,et al.Erratum to:The COMETOpen-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer[J].Annals of Surgical Oncology,2016,24(2):1.
[19]严海,黄丹,胡清林,等.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆miR-21表达的影响[J].现代生物医学进展,2017,17(17):3291-3294.
[2]孙翠玲,徐晓宇,高莹莹,等.奥沙利铂联合替吉奥治疗晚期结肠癌患者的临床疗效与安全性[J].中国临床药理学杂志,2017,33(16):1540-1542.
[3]Kap E J,Seibold P,Scherer D,et al.SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients[J].International Journal of Cancer,2016,138(12):2993-3001.
[4]宗明珠,冯婉婷,于伟勇,等.奥沙利铂联合卡培他滨或替吉奥治疗晚期结直肠癌临床疗效的比较[J].肿瘤,2018,38(3):229-234.
[5]左富义,于波,聂玉辉.替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂方案治疗结直肠癌的疗效比较研究[J].中国全科医学,2017,20(29):3612-3616.
[6]Wein A,Siebler J,Wolff K,et al.Weekly High-dose 5-Fluorouracil as24-hour Infusion Combined with Sodium Folinic Acid(AIO regimen)Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer(CRC)[J].Anticancer Research,2017,37(7):3771.
[7]沈旭东,庄志祥,甘蕾,等.每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析[J].肿瘤防治研究,2016,43(5):400-403.
[8]刘君,肖扬,郭建雄,等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究,2016,43(1):72-77.
[9]万一元,惠红霞,王晓炜,等.卡培他滨或替吉奥联合奥沙利铂方案治疗进展期胃癌的疗效及安全性[J].中华肿瘤杂志,2016,38(1):28-34.
[10]展军.奥沙利铂联合替吉奥方案与XELOX方案在晚期结直肠癌治疗中的疗效及毒副作用对比[J/OL].临床医药文献电子杂志,2016,3(59):11865-11866.
[11]Chen J,Luo X,Xie G,et al.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy[J].Medicine,2016,95(19):e3652.
[12]李方,李楠.华蟾素胶囊联合奥沙利铂、替吉奥方案治疗中晚期结直肠癌临床疗效[J].临床军医杂志,2016,44(10):1033-1036.
[13]张瑞亮,李文见,姜统杰.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者疗效对比[J].癌症进展,2017,15(2):196-198.
[14]宁洁,焦洋,李敏,等.替吉奥联合奥沙利铂一线治疗晚期结直肠癌的疗效及安全性研究[J].安徽医药,2017,21(9):1669-1673.
[15]Fernandes G D S,Braghiroli M I,Artioli M,et al.Combined oxaliplatin,irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer patients[J].Annals of Oncology,2016,27(suppl 2):ii45-ii46.
[16]李响.奥沙利铂联合替吉奥与雷替曲塞治疗晚期结肠癌患者的疗效观察[J].中国现代药物应用,2017,11(17):91-92.
[17]李鹏,李成浩.奥沙利铂联合替吉奥治疗晚期结直肠癌的临床疗效观察[J].中国实用医药,2017,12(7):143-144.
[18]Kataoka M,Kanda M,Ishigure K,et al.Erratum to:The COMETOpen-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer[J].Annals of Surgical Oncology,2016,24(2):1.
[19]严海,黄丹,胡清林,等.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者血浆miR-21表达的影响[J].现代生物医学进展,2017,17(17):3291-3294.